VaxInnate Corporation’s M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study

CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation announced today that its M2e universal influenza vaccine candidate was safe and immunogenic in its first Phase I clinical trial, raising hopes for a universal influenza vaccine that could provide protection against seasonal and pandemic influenza strains.